Aroplatin and Capecitabine in Patients With Advanced Colorectal Cancer Resistant to Standard Therapies
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study is a Phase I/II study. In Phase I of this study, the objective is to determine the
maximum tolerated dose (MTD) of combination therapy with Aroplatin and capecitabine in
subjects with unresectable, local recurrence or distant metastases of colorectal cancer
refractory to 5-FU/leucovorin and irinotecan. In Phase II, the primary objective is to
evaluate the response proportion and duration with Aroplatin/capecitabine therapy. Secondary
objectives are to evaluate frequency and severity of adverse events.